B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...
News-Medical.Net on MSN1d
Researchers develop TIM-3 decoy to enhance CAR-T therapy effectiveness for B-ALL tumorsB-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...
Zavier Sexton, Graham Smith, Bryce Miller and Natalie Vulhop were honored as young heroes at the 2025 CBJ Foundation ...
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...
Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...
Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...
Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback